$1.7M Benefit For Drug Firms

Health Canada met privately with pharmaceutical executives to weigh a “cost-benefit analysis” of a new drug safety law, says the department. The closed meetings last October prompted regulators to waive a multi-million dollar requirement that drug companies automatically submit all clinical data when licensing new products: ‘We would not require case reports when a person has died.’

This content is for Blacklock’s Reporter members only. Please login to view this content. (Register here.)

Back to Top